# Trevi Therapeutics to Present Phase 2b CORAL Trial Data at CHEST 2026

- URL: https://stocks.freetheai.org/news/trevi-therapeutics-to-present-phase-2b-coral-trial-data-at-chest-2026-074570
- Published: 2026-10-13T11:30:00Z
- Category: company_news; sentiment: neutral; impact: low
- Symbols: [NASDAQ:TRVI](https://stocks.freetheai.org/symbols/NASDAQ-TRVI)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Trevi Therapeutics, Inc. (NASDAQ:TRVI) announced that findings from its Phase 2b CORAL trial were accepted for an oral presentation at the CHEST 2026 Annual Meeting in Phoenix, Arizona. Professor Philip Molyneaux will share patient-reported outcomes on October 20, 2026, evaluating oral nalbuphine ER for treating chronic cough in individuals with idiopathic pulmonary fibrosis.

Chronic cough linked to idiopathic pulmonary fibrosis affects roughly two-thirds of the estimated 140,000 patients in the United States, and currently has no treatments approved by the Food and Drug Administration. The 165-patient Phase 2b CORAL study tested three dosage levels of nalbuphine ER against a placebo over a six-week treatment period, tracking changes in objective 24-hour cough frequency as well as patient-reported measures.

Investors and clinicians will monitor the detailed presentation on October 20 for full patient-reported outcome data, which could shed further light on the drug's therapeutic potential. Shares of Trevi Therapeutics, Inc. were trading at $12.93, down 1.97% on the day.

## Key points

- Trevi Therapeutics will deliver an oral presentation on its Phase 2b CORAL trial at the CHEST 2026 Annual Meeting on October 20.
- The trial evaluated three dose levels of nalbuphine ER against placebo in 165 patients with idiopathic pulmonary fibrosis experiencing chronic cough.
- Results highlight patient-reported outcomes following a six-week treatment period with the investigational oral therapy.
- There are currently no FDA-approved treatments for chronic cough in patients with idiopathic pulmonary fibrosis in the United States.

## Questions and answers

### When will Trevi Therapeutics present its Phase 2b trial data?

Trevi Therapeutics is scheduled to present its Phase 2b CORAL trial findings on October 20, 2026, at the CHEST 2026 Annual Meeting in Phoenix, Arizona.

### What condition is Trevi Therapeutics developing nalbuphine ER for?

Nalbuphine ER is an investigational oral therapy being developed to treat chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough.